Floatz logo

REGADENOSON

Sickle Cell Disease

St. Jude Children's Research HospitalSmall moleculePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
65/ 100

Competitive context

134 Active assets in the Sickle Cell Disease cohort.

Asset / SponsorPhaseRating
Glutamine
Ain Shams University
Phase 4BBB
Hydroxyurea
St. Jude Children's Research Hospital
Phase 4BB
MAGNESIUM METALLICUM
Medical College of Wisconsin
Phase 3BB
Crizanlizumab
Novartis Pharmaceuticals
Phase 4BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

REGADENOSON is also rated in:

anaplastic oligodendrogliomaDormant
CC
Indicative ·
43 / 100
View asset →
anaplastic astrocytomaDormant
CC
Indicative ·
41 / 100
View asset →
malignant gliomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →